AstraZeneca announced Saturday that it received confirmation from the United Kingdom's Medicines Health Regulatory Authority that it was safe to resume clinical trials for the company's coronavirus vaccine in the U.K. after they were paused over safety concerns. The vaccine candidate, which was developed in partnership between AstraZeneca and the University of Oxford, is considered one of the world's most promising, but phase three of its trials was temporarily halted after a woman in the U.K. reportedly displayed neurological symptoms consistent with a spinal inflammatory disorder called transverse myelitis after receiving the vaccine. The World Health Organization's Chief Scientist Dr. Soumya Swaminathan said there was no reason to be "overly discouraged" by the pause since "there are ups and downs in research."